CORRIGENDUM Expression and mutation status of ... - Nature
Recommend Documents
Jul 28, 2009 - International Journal of Obesity (2010) 34, 215; doi:10.1038/ijo.2009.246 ... 1001â1006; doi:10.1038/ijo.2009.140; published online 28.
Jeffrey R. Anderson is at the Howard Hughes Medical Institute and. Department of Human Genetics, University of Chicago, Chicago, Illinois 60637, USA.
erroneously stated as 'r divided by the square root of 2' instead of 'r multiplied ... intensity for two-photon microscopy was given as '103 times E' instead of '106 ...
CORRECTIONS & AMENDMENTS. CORRIGENDUM doi:10.1038/nature12667. Corrigendum: APOBEC3B is an enzymatic source of mutation in breast cancer.
from the first (1953±1973) to the second (1972±1990) observation period shall be taken with some caution, and specially for the men they are not valid.
Apr 26, 2013 - Cetuximab in a Large Panel of Patient Derived Colorectal ... xenograft models from fresh tumor specimens of 239 patients with CRC of all four ...
Apr 26, 2013 - xenograft models was treated with cetuximab, bevacizumab and oxaliplatin as single agents. Mutation status of KRAS. (G12, G13, A146T) ...
LETTER TO THE EDITOR. IDH mutation status in prostate cancer. Oncogene (2012) 31, 3826; doi:10.1038/onc.2011.546; published online 28 November 2011.
Jan 5, 2006 - CORRIGENDUM: NK cells promote islet allograft tolerance via a perforin- dependent mechanism. J N Beilke, N R Kuhl, L Van Kaer & R G Gill.
Jan 5, 2006 - In the version of this article initially published, some information about sources was omitted. The citation of the data source for Table 1 should.
cell proliferation (for example, CCNB2, CDCA5, CENPA, and. UBE2C), while the genes with lower relative expression showed more diverse functions and were ...
Rapidly maturing variants of the Discosoma red fluorescent protein (DsRed). B.J. Bevis and B.S. Glick. Nat. Biotechnol. 20, 83â87 (2002). On p. 83 of this report, ...
and veterans of operation Ranch Hand. JOEL E. MICHALEK, JAMES L. PIRKLE, LARRY L. NEEDHAM, DONALD G. PATTERSON Jr.,. SAMUEL P. CAUDILL ...
... Elkadri, Judy Cho, Deborah Proctor, Philippe Goyette, John Rioux and Alain Bitton ... with small bowel Crohn's disease was inadvertently written as (75% vs.
Mar 15, 2008 - Abstract. Cetuximab is a monoclonal antibody that targets the human epidermal growth factor receptor (EGFR). Although approved for use in ...
May 15, 2014 - McArthur GA, Ribas A, Chapman PB, Flaherty KT, Kim KB, Puzanov I, ..... Ott PA, Henry T, Baranda SJ, Frleta D, Manches O, Bogunovic D, ...
Dec 24, 2013 - Intra-patient heterogeneity of BRAF mutation status: fact or fiction? A M Menzies1, J S Wilmott1, G V Long1 and R A Scolyer*,1,2. 1Melanoma ...
Aug 28, 2009 - anti-CD117 antibody and KIT mutational analysis by gene sequencing of exons 11, 13, and 17 were performed. Eighty-one percent of acral ...
Altered Expression of -Catenin without Genetic. Mutation in Intrahepatic Cholangiocarcinoma. Keishi Sugimachi, M.D., Ken-ichi Taguchi, M.D., Shin-ichi Aishima, ...
Oliver Weichenrieder, Bi-Cheng Wang, Michel O Steinmetz, Martin Caffrey ... Dörte DiFiore, Despina Milathianaki, Alan R Fry, Alan Miahnahri, William E White, ...
Among patients with variant LH, five silent mutations were identified in. 87.5% of patients with ovulatory disorders, whereas only a few silent mutations were ...
CORRIGENDUM. Atypical lymphocytic leukemia and mantle cell lymphoma immunologically very close: flow cytometric distinction by the use of CD20 and CD54 ...
CORRIGENDUM Expression and mutation status of ... - Nature
CORRIGENDUM. Expression and mutation status of candidate kinases in multiple myeloma. JO Claudio, F Zhan, L Zhuang, R Khaja, YX Zhu, K Sivananthan, ...
Leukemia (2008) 22, 889–890 & 2008 Nature Publishing Group All rights reserved 0887-6924/08 $30.00 www.nature.com/leu
CORRIGENDUM Expression and mutation status of candidate kinases in multiple myeloma JO Claudio, F Zhan, L Zhuang, R Khaja, YX Zhu, K Sivananthan, S Trudel, E Masih-Khan, R Fonseca, PL Bergsagel, SW Scherer, J Shaughnessy and AK Stewart
information in Supplementary Table 1, which shows the complete list of 280 probe IDs representing 185 unique kinases as presented in the heat map of Figure 2 below.
Correction to: Leukemia (2007) 21, 1124–1127. doi:10.1038/sj.leu.2404612 The authors of the above paper inadvertently submitted the incorrect supplementary information. They have corrected this
% Scanned 0
20
40
60
The authors apologize for any inconvenience caused.
, 80
100
ACVR2 FLT3 EPHA 4 BTK GUCY2F EPHB6 MAP3K9 ACK1
FGFR3
CSK ABL1
ILK SRC ROR2 MET CKS1B MAP3K14 FGFR3 FGR EPHB4 PTK2 ROS1 KIT IGF1R NTRK3 EGFR ABL1 KDR EPHA3 FES
JAK3
MET KIT
MLK4 JAK3 CSK PIK3CA
ROR2
Figure 2 (a) Sequence screening of 31 genes in a panel of 32 myeloma cell lines. The graph shows the percentage of kinase domains screened in the 31 kinases. (b) Heat map showing the groups of normals, primary myeloma samples and cell lines when expression of kinase genes was used for cluster analysis. (c) Nucleotide sequence changes in FGFR3, EGFR, EPHB4 and GUCY2F showing changes in the boxed sequence.
